Descriptor: "emperor-reduced study" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"emperor-reduced study"' showing total 3 results

Start Over Descriptor "emperor-reduced study"

Author: A. Yu. Lebedeva, O. M. Koteshkova, O. N. Dzhioeva, S. R. Gilyarevsky, T. M. Uskach, M. S. Novikova, Ya. A. Orlova, V. Yu. Kalashnikov, D. V. Privalov, N. A. Ananicheva, M. Yu. Gilyarov, and A. D. Erlikh
Subjects: empagliflozin, chronic heart failure, cardiovascular mortality, chronic kidney disease, emperor-reduced study, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract: The results of the international multicenter study EMPEROR-REDUCED were reviewed the on-line scientific meeting of Moscow experts on October 30, 2020. Some proposals and recommendations for further study of the cardiovascular and renal effects of empagliflozin and its use in clinical practice in patients with chronic heart failure with reduced ejection fraction were accepted.
Published: 2021
Full Text: View/download PDF

Author: A. S. Galyavich, I. V. Fomin, I. R. Gaisin, F. V. Valeeva, N. G. Vinogradova, A. S. Salasyuk, E. I. Tarlovskaya, N. R. Khasanov, A. M. Shutov, E. N. Volodina, L. V. Grekhova, P. S. Guseva, D. V. Duplyakov, O. V. Zanozina, Yu. V. Zolotova, S. V. Kanysheva, Z. F. Kim, S. K. Kononov, V. P. Kuzmin, S. S. Markiyanova, M. V. Menzorov, S. A. Pomosov, A. P. Rebrov, and S. N. Tolstov
Subjects: empagliflozin, heart failure, cardiovascular mortality, chronic kidney disease, emperor-reduced study, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract: At an online meeting of experts held on May 14, 2021 additional research results on a sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with reduced ejection fraction were considered. According to the data from the EMPEROR-Reduced international study, cardiovascular and renal effects of empagliflozin therapy in patients with and without type 2 diabetes (T2D) were analyzed. A number of proposals and recommendations was accepted regarding the further study of cardiovascular and renal effects of empagliflozin and its use in clinical practice in patients with heart failure, regardless of the T2D presence.
Published: 2022
Full Text: View/download PDF

Author: N A Ananicheva, M. Yu. Gilyarov, T. M. Uskach, M. S. Novikova, A. Yu. Lebedeva, A. D. Erlikh, Ya A Orlova, S. R. Gilyarevsky, V. Yu. Kalashnikov, O. N. Dzhioeva, D. V. Privalov, and O. M. Koteshkova
Subjects: medicine.medical_specialty, empagliflozin, emperor-reduced study, RM1-950, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, cardiovascular mortality, Empagliflozin, medicine, Diseases of the circulatory (Cardiovascular) system, Pharmacology (medical), In patient, 030212 general & internal medicine, Intensive care medicine, Cardiovascular mortality, Ejection fraction, biology, business.industry, biology.organism_classification, medicine.disease, chronic heart failure, Clinical Practice, Multicenter study, RC666-701, Heart failure, Emperor, Therapeutics. Pharmacology, Cardiology and Cardiovascular Medicine, business, chronic kidney disease
Abstract: The results of the international multicenter study EMPEROR-REDUCED were reviewed the on-line scientific meeting of Moscow experts on October 30, 2020. Some proposals and recommendations for further study of the cardiovascular and renal effects of empagliflozin and its use in clinical practice in patients with chronic heart failure with reduced ejection fraction were accepted.
Published: 2021

Books, media, physical & digital resources

Searchworks